除了作为治疗HIV感染者的长效疗法以外,吉利德科学也在进行临床试验,评估lenacapavir作为暴露前预防(PrEP)疗法的潜力。在临床前的非人灵长类动物研究中,一次低剂量或高剂量lenacapavir注射能够将感染风险分别降低86%(p=0.0061)和96%(p=0.0002)。
猎药人网站指出,lenacapavir是小分子药物开发的经典案例,并预祝它在今后的临床开发和批准过程中传来更多的好消息。
参考资料:
[1] Small Molecule of the Year – 2020. Retrieved March 28,2021, from https://drughunter.com/2020smotygs/
[2] Gilead’s Investigational Lenacapavir DemonstratesSustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI.Retrieved March 28, 2021, from https://www.gilead.com/news-and-press/press-room/press-releases/2021/3/gileads-investigational-lenacapavir-demonstrates-sustained-long-acting-efficacy-through-week-26-in-data-presented-at-croi
[3] Gilead and Merck Announce Agreement to Jointly Developand Commercialize Long-Acting, Investigational Treatment Combinations ofLenacapavir and Islatravir in HIV. Retrieved March 28, 2021, from https://www.gilead.com/news-and-press/press-room/press-releases/2021/3/gilead-and-merck-announce-agreement-to-jointly-develop-and-commercialize-longacting-investigational-treatment-combinations-of-lenacapavir-and-islatr
[4] Capsid. Retrieved March 28, 2021, from https://clinicalinfo.hiv.gov/en/glossary/capsid
[5] Quinn et al., (2018). Dynamic regulation of HIV-1 capsidinteraction with the restriction factor TRIM5α identified by magic-anglespinning NMR and molecular dynamics simulations. PNAS, https://doi.org/10.1073/pnas.1800796115
*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。▽关注【药明康德】微信公众号